July 17, 2023 12:30-1:30 pm US EST
Topics covered will include:
How financial portfolio theory can be applied to rare disease therapeutics, and when do they fail?
What is the role of patient advocacy and philanthropy?
How can expensive one-time therapies be covered for all?
What can we do to accelerate progress in this space?
Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management and co-founder and chief investment strategist of QLS Advisors LLC, a healthcare analytics and investment advisory firm. His healthcare-related research interests include: new financial engineering tools and business models for drug and device development and healthcare delivery; statistical methods for incorporating patient preferences into the drug approval process; predicting clinical trial outcomes via machine learning techniques; and novel funding and reimbursement models for creating a robust gene therapy ecosystem. He is a co-founder and director of BridgeBio Pharma, a director of AbCellera, Atomwise, and Vesalius, and a member of the advisory board of the American Cancer Society’s BrightEdge Impact Fund. Dr. Lo received his B.A. in economics from Yale University and his A.M. and Ph.D. in economics from Harvard University.